Characteristics of poloxamer thermosensitive in situ gel of dexamethasone sodium phosphate

Yaoxue Xuebao

Volumn 43, Issue 2, 2008, Pages 208-213

  Li, Xin Yu ^a   Zhu, Zhao Jing ^a   Cheng, An Yuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Elastic modulus; Gelation temperature; Poloxamer; Sol gel transition temperature; Stable viscosity; Thermosensitive in situ gel

Indexed keywords

DEXAMETHASONE; DEXAMETHASONE 21-PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE; DRUG DERIVATIVE; POLOXAMER;

ARTICLE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; FLOW KINETICS; GEL; METHODOLOGY; TEMPERATURE; VISCOSITY;

DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; GELS; POLOXAMER; RHEOLOGY; TEMPERATURE; VISCOSITY;

EID: 42149163424     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Paavola A, Yliruusi J, Kajimoto Y, et al. Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block [J]. Pharm Res, 1995,12:1997 -2002.
2. Amiji MM, Lai PK, Shenoy DB, et al. Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation [J]. Pharm Dev Technol, 2002, 7: 195 - 202.
3. Boodhwani M, Feng J, Mieno S, et al. Effects of purified poloxamer 407 gel on vascular occlusion and the coronary endothelium [J]. Eur J Cardiothorac Surg, 2006, 29 : 736 - 741.
4. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice [J]. Pharm Res, 1992,9:425 - 434.
5. Wenzel JG, Balaji KS, Koushik K, et al. Pluronic® F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle [J]. J Control Release, 2002,85:51 - 59.
6. Johnston TP, Miller SC. Toxicological evaluation of poloxamer vehicles for intramuscular use [J]. J Parenter Sci Technol, 1985,39:83 - 89.
7. Chen G, Hou SX, Liu J, et al. Study on dexamethasone thermosensitive in situ gel for treating deafness [J]. Chin Phar J, 2006,41:685 - 688.
8. Liu Y, Lu WL, Wang JC, et al. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization [J]. J Control Release, 2007,117:387 - 395.
9. Alexandridis P, Hatton TA. Poly (ethylene oxide)-poly (propylene oxide) -poly (ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modelling [J]. Colloids Surf B Biointerfaces, 1995,96: 1 - 46.
10. Alexandridis P, Holzwarth JF, Hatton TA. Micellization of poly (ethylene oxide) -poly (propylene-oxide) -poly (ethylene oxide) triblock copolymers in aqueous solutions : thermodynamics of copolymer association [J]. Macromolecules, 1994,27:2414 - 2425.
11. Zhang L, Parsons DL, Navarre C, et al. Development and in vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur [J]. J Control Release, 2002,85:73 - 81.
12. Barichello JM, Morishita M, Takayama K, et al. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats [J]. Int J Pharm, 1999,184:189 - 198.